https://www.selleckchem.com/products/gw6471.html
The heterogeneity of triple-negative breast cancer (TNBC) confers variable response to chemotherapy that results in poor outcome and relapse. Due to lack of targeted therapy, there is a need to provide molecular classification of TNBC and identify probable therapeutic targets. We classified TNBC into surrogate molecular subtypes by immunohistochemistry and evaluated hotspot mutations (N = 8 in PIK3CA (exon 4, 9, and 2 and AKT1 (exon 2) in TNBC subtypes by Sanger sequencing. TNBCs were classified into Basal-like 1(BL1) (n = 20, 25%),
Like
Comment
Share
